

## DEPARTMENT OF HEALTH & HUMAN SERVICES

#### PUBLIC HEALTH SERVICE NATIONAL INSTITUTES OF HEALTH

FOR US POSTAL SERVICE DELIVERY:
Office of Laboratory Animal Welfare
6700B Rockledge Drive, Suite 2500, MSC 6910
Bethesda, Maryland 20892-6910
Home Page: http://grants.nih.gov/grants/olaw/olaw.htm

October 16, 2019

FOR EXPRESS MAIL:
Office of Laboratory Animal Welfare
6700B Rockledge Drive, Suite 2500
Bethesda, Maryland 20817
Telephone: (301) 496-7163
Facsimile: (301) 402-7065

Re: Animal Welfare Assurance A3168-01 [OLAW Case P]

Dr. Ping Wang Chief Scientific Officer Feinstein Institute for Medical Research 350 Community Drive Manhasset, NY 11030

Dear Dr. Wang,

The Office of Laboratory Animal Welfare (OLAW) acknowledges receipt of your October 3, 2019 letter reporting an instance of noncompliance with the PHS Policy on Humane Care and Use of Laboratory Animals at the Feinstein Institutes for Medical Research. According to the information provided, OLAW understands that four mice were subjected to an approved procedure but were not monitored as per protocol and were not euthanized at the appropriate humane endpoint.

The corrective actions consisted of counseling the laboratory staff on their responsibilities and on following the protocol, having the Principal Investigator hold ongoing staff meetings to discuss animal protocol issues, having the veterinarian or experienced staff observe the performance of intraperitoneal injections, and placing the laboratory under enhanced post-approval monitoring.

Based on its assessment of this explanation, OLAW understands that measures have been implemented to correct and prevent recurrence of this problem. OLAW concurs with the actions taken by the institution to comply with the PHS Policy.

Sincerely,

(b) (6)

Axel Wolff, M.S., D.V.M. Deputy Director Office of Laboratory Animal Welfare

cc: IACUC Chair

Director, Animal Welfare Office



350 Community Drive Manhasset, NY 11030 Tel: (516) 562-3411 Fax: (516) 562-1022 Email: pwang@northwell.edu

### VIA E-MAIL

October 3, 2019

Dr. Axel Wolff
Director, Division of Compliance Oversight
Office of Laboratory Animal Welfare
National institutes of Health
Rockledge 1, Suite 360, MSC 7982
6705 Rockledge Drive
Bethesda, MD 20892-7982
E-mail: olawdco@mail.nih.gov

PHS Assurance Number: D16-00107 (A3168-01) Grant # 1R1GM132672-01

Dear Dr. Wolff:

In follow to a verbal report provided to you by our IACUC Director on 10/3/19, I am writing to inform the Office of Laboratory Animal Welfare of an incident of serious non-compliance that occurred at the Feinstein Institute for Medical Research. The research in question is PHS funded therefore, we are reporting this protocol related incident under the terms and conditions of our federal assurance.

Consistent with the IACUC approved protocol, four mice underwent a non-surgical procedure however, the responsible study personnel failed to adhere to experimental endpoints, early euthanasia criteria, and post-procedural monitoring as outlined in the approved protocol. The responsible party was previously trained and is familiar with protocol and animal use expectations.

#### Corrective Actions:

- The Principal Investigator (PI) will discuss this incident with study personnel, review assigned responsibilities and animal
  use activities ensuring they will be conducted in accordance with the approved protocol.
- The PI will begin convening regularly scheduled meetings for lab personnel to specifically discuss their animal protocols, progress updates, and review approved modifications.
- 3. Recommend observation by veterinarian or experienced personnel of the i.p. injection technique.
- The Animal Welfare Office will conduct additional post-approval monitoring/continuing review assessments.

Please contact me with any questions or concerns.

Sincerely,

(b) (6)

Ping Wang, MD Chief Scientific Officer Institutional Official

cc: Dr. Kathryn Bayne, Chief Executive Officer, AAALAC International, <a href="mailto:kbayne@aaalac.org">kbayne@aaalac.org</a>; Dr. Max Brenner, IACUC Chairman <a href="mailto:mbrenner@northwell.edu">mbrenner@northwell.edu</a>; Director, Animal Welfare Office <a href="mailto:iacuc@northwell.edu">iacuc@northwell.edu</a>

# Wolff, Axel (NIH/OD) [E]

From:

Wolff, Axel (NIH/OD) [E]

Sent:

Tuesday, October 8, 2019 6:33 AM

To:

Aparicio, Michelle

Subject:

RE: Report to OLAW

Thank you for this report, Ms. Aparicio. I will send a response soon. In future please send all final reports to the email address noted in your letter. You are welcome to send all questions and preliminary reports to me directly, and of course you may call.

Axel Wolff

From: Aparicio, Michelle <MAparici@northwell.edu>

Sent: Monday, October 7, 2019 4:08 PM

To: Wolff, Axel (NIH/OD) [E] <wolffa@od.nih.gov>

Cc: kbayne@aaalac.org; Wang, Ping - MD <PWang@northwell.edu>; Brenner, Max <MBrenner@northwell.edu>; IACUC

<IACUC@northwell.edu> Subject: Report to OLAW

Good afternoon Dr. Wolff,

In follow up to a preliminary verbal report 10/3/19, attached please find a final report including a full explanation of circumstances and actions taken consistent with NOD-OD-05-034.

Kindly advise if you have any questions or require additional information.

Thank you.

#### Michelle Aparicio, CPIA

Director, Animal Welfare Office Institutional Animal Care & Use Committee (IACUC) Institutional Biosafety Committee (IBC) The Feinstein Institutes for Medical Research - Northwell Health Co-Chair, PRIM&R CPIA Council (CCPIA®) 125 Community Drive Great Neck, NY 11021

Tel:

Email: maparici@northwell.edu http://www.feinsteininstitute.org/

The information contained in this electronic e-mail transmission and any attachments are intended only for the use of the individual or entity to whom or to which it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient, or the employee or agent responsible for delivering this communication to the intended recipient, you are hereby notified that any dissemination, distribution, copying or disclosure of this communication and any attachment is strictly prohibited. If you have received this transmission in error, please notify the sender immediately by telephone and electronic mail, and delete the original communication and any attachment from any computer, server or other electronic recording or storage device or medium. Receipt by anyone other than the intended recipient is not a waiver of any attorney-client, physician-patient or other privilege.